<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00275535</url>
  </required_header>
  <id_info>
    <org_study_id>124-01</org_study_id>
    <nct_id>NCT00275535</nct_id>
  </id_info>
  <brief_title>The Comparison of Tacrolimus and Sirolimus Immunosuppression Based Drug Regimens in Kidney Transplant Recipients</brief_title>
  <official_title>A Prospective, Randomized Trial of Calcineurin-Inhibitor Withdrawal in Renal Allograft Recipients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Wyeth is now a wholly owned subsidiary of Pfizer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Genzyme, a Sanofi Company</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Roche Pharma AG</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Mayo Clinic</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study was done to find out which treatment, tacrolimus or sirolimus, leads to better
      long-term kidney function in kidney transplant patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The aim of this study was to compare the complete avoidance of calcineurin inhibitors (CI)
      using a sirolimus-based immunosuppressive regimen to a tacrolimus-based regimen in kidney
      transplantation. This study was a prospective open-label trial randomizing patients to
      receive tacrolimus, mycophenolate mofetil and prednisone or sirolimus, mycophenolate mofetil
      and prednisone. All patients received antithymocyte globulin induction. All rejection
      episodes were proven by biopsy. The hypothesis was that CI free immunosuppression after
      kidney transplantation will lead to an increase in glomerular filtration rate (GFR) at one
      year after kidney transplantation.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2001</start_date>
  <completion_date type="Actual">December 2008</completion_date>
  <primary_completion_date type="Actual">November 2007</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Glomerular filtration rate (GFR) (iothalamate clearance) at 12 months following transplantation</measure>
    <time_frame>12 months following transplantation</time_frame>
    <description>Glomerular filtration rate (Iothalamate clearance) at 12 months following transplantation.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>GFR (iothalamate clearance) at other time points</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Other measures of renal function (serum creatinine, proteinuria and albuminuria)</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acute rejection both early and after tacrolimus withdrawal</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient and graft survival</measure>
    <time_frame>24 months after transplantation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complications-especially hypertension, diabetes, dyslipidemia</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">165</enrollment>
  <condition>Kidney Diseases</condition>
  <arm_group>
    <arm_group_label>Tacrolimus</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Calcineurin inhibitor arm, consisting of treatment with tacrolimus, mycophenolate mofetil, and prednisone.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sirolimus</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Calcineurin inhibitor-free arm, consisting of treatment with rapamycin, mycophenolate mofetil, and prednisone.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Anti-thymocyte globulin</intervention_name>
    <description>Thymoglobulin 1.5 mg/kg/d (days 0,1,2,4,6)</description>
    <arm_group_label>Tacrolimus</arm_group_label>
    <arm_group_label>Sirolimus</arm_group_label>
    <other_name>Thymoglobulin</other_name>
    <other_name>Atgam</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mycophenolate mofetil</intervention_name>
    <description>Mycophenolate mofetil 750 mg p.o. b.i.d.- maintenance</description>
    <arm_group_label>Tacrolimus</arm_group_label>
    <arm_group_label>Sirolimus</arm_group_label>
    <other_name>CellCept</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prednisone</intervention_name>
    <description>Prednisone 500 mg/day initially, tapered to 5 mg/day by day 92</description>
    <arm_group_label>Tacrolimus</arm_group_label>
    <arm_group_label>Sirolimus</arm_group_label>
    <other_name>Deltasone</other_name>
    <other_name>Liquid Pred</other_name>
    <other_name>Meticorten</other_name>
    <other_name>Orasone</other_name>
    <other_name>Prednicen-M</other_name>
    <other_name>Prednicot</other_name>
    <other_name>Sterapred</other_name>
    <other_name>Sterapred DS</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tacrolimus</intervention_name>
    <description>Tacrolimus - maintain trough levels of 6-8 ng/ml (whole blood Imx assay)</description>
    <arm_group_label>Tacrolimus</arm_group_label>
    <other_name>Prograf</other_name>
    <other_name>Advagraf</other_name>
    <other_name>Protopic</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sirolimus</intervention_name>
    <description>Rapamycin 3 to 5 mg/day; adjust to the high-performance liquid chromatography (HPLC) blood level 15 to 20 ng ml</description>
    <arm_group_label>Sirolimus</arm_group_label>
    <other_name>Rapamune</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Living and deceased donor kidney transplant recipients at the Mayo Clinic, Rochester,
             Minnesota

        Exclusion Criteria:

          -  Patients with type 1 diabetes less than 50 years of age who receive a living donor
             kidney transplant followed by a pancreas transplant

          -  Pediatric patients (&lt;18 years of age)

          -  Multi-organ transplants (e.g., kidney-pancreas, kidney-liver)

          -  ABO-incompatible or positive crossmatch recipients (ABO incompatibility is an immune
             system reaction that occurs when blood from two different and incompatible blood types
             are mixed together.)

          -  Patients with severe hyperlipidemia (serum cholesterol &gt;350 mg/dl or serum
             triglycerides &gt;500 mg/dl

          -  Patients with severe leukopenia (White Blood Cell count [WBC]&lt;3000 10^3/ml)

          -  Patients unwilling to return to the transplant center for late follow-up visits

          -  Body mass index (BMI) â‰¥ 32 with incisional problems post transplant (as determined by
             renal transplant surgeon
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mark D. Stegall, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://clinicaltrials.mayo.edu</url>
    <description>Mayo Clinic Clinical Trials</description>
  </link>
  <results_reference>
    <citation>Dean PG, Grande JP, Sethi S, Park WD, Griffin MD, Cosio FG, Larson TS, Stegall MD. Kidney transplant histology after one year of continuous therapy with sirolimus compared with tacrolimus. Transplantation. 2008 Apr 27;85(8):1212-5. doi: 10.1097/TP.0b013e31816a8ae6.</citation>
    <PMID>18431244</PMID>
  </results_reference>
  <results_reference>
    <citation>Larson TS, Dean PG, Stegall MD, Griffin MD, Textor SC, Schwab TR, Gloor JM, Cosio FG, Lund WJ, Kremers WK, Nyberg SL, Ishitani MB, Prieto M, Velosa JA. Complete avoidance of calcineurin inhibitors in renal transplantation: a randomized trial comparing sirolimus and tacrolimus. Am J Transplant. 2006 Mar;6(3):514-22.</citation>
    <PMID>16468960</PMID>
  </results_reference>
  <verification_date>December 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 10, 2006</study_first_submitted>
  <study_first_submitted_qc>January 10, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 12, 2006</study_first_posted>
  <last_update_submitted>December 6, 2011</last_update_submitted>
  <last_update_submitted_qc>December 6, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 8, 2011</last_update_posted>
  <responsible_party>
    <name_title>Mark D. Stegall, M.D.</name_title>
    <organization>Mayo Clinic</organization>
  </responsible_party>
  <keyword>kidney transplantation</keyword>
  <keyword>immunosuppression</keyword>
  <keyword>calcineurin inhibitor</keyword>
  <keyword>sirolimus</keyword>
  <keyword>chronic allograft nephropathy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prednisone</mesh_term>
    <mesh_term>Sirolimus</mesh_term>
    <mesh_term>Everolimus</mesh_term>
    <mesh_term>Mycophenolic Acid</mesh_term>
    <mesh_term>Tacrolimus</mesh_term>
    <mesh_term>Thymoglobulin</mesh_term>
    <mesh_term>Antilymphocyte Serum</mesh_term>
    <mesh_term>Calcineurin Inhibitors</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

